We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in Verona Pharma in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

Holders
–
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
-$359K
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
–

VRNA Hedge Fund Activity: Q1 2026 in Review

0 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2026, worth a combined $0 — down 100% from $359K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of VRNA and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $359K sold.

  • 0 institutional investors held Verona Pharma (VRNA) as of Q1 2026, down from 1 in Q4 2025.
  • Funds reported $0 of Verona Pharma stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Verona Pharma positions in Q1 2026 and 1 closed out, a net change of -1 holder.
  • The largest Verona Pharma seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $359K sold.

Based on aggregated 13F filings for Q1 2026.